Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Elsevier Science full text link Elsevier Science Free PMC article
Full text links

Actions

Share

.2010 Oct;122(4):212-8.
doi: 10.1016/j.jsbmb.2010.06.009. Epub 2010 Jun 25.

The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects

Affiliations

The potent synthetic androgens, dimethandrolone (7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone, do not require 5α-reduction to exert their maximal androgenic effects

Barbara J Attardi et al. J Steroid Biochem Mol Biol.2010 Oct.

Abstract

Dimethandrolone (DMA: 7α,11β-dimethyl-19-nortestosterone) and 11β-methyl-19-nortestosterone (MNT) are potent androgens in development for hormonal therapy in men. As 5α-reduced androgens, such as 5α-dihydrotestosterone (DHT), may raise the risk of benign prostate hyperplasia, accelerate the development of prostate carcinoma, and increase male pattern baldness and acne, we investigated the role of 5α-reduction in the androgenic activity of DMA and MNT. The authentic 5α-reduced metabolites, 5α-dihydroDMA (5α-DHDMA) and 5α-dihydroMNT (5α-DHMNT), were prepared by chemical synthesis and compared in vitro and in vivo to the parent compounds. Both 5α-reduced androgens bound with high affinity to the rat androgen receptor (AR) and were potent inducers of transactivation of 3XHRE-LUC in CV-1 cells cotransfected with a human AR expression plasmid. To examine in vivo androgenic (stimulation of ventral prostate [VP] and seminal vesicle [SV] weights) and anabolic (stimulation of levator ani [LA] muscle weights) activity, 22-day-old castrate male rats were treated sc for 7 days with various doses of DMA, 5α-DHDMA, or testosterone (T) or MNT, 5α-DHMNT, or T and necropsied on day 8. 5α-DHDMA was at least threefold more potent than T in stimulating growth of the VP but only 30-40% as potent as DMA. 5α-DHMNT was four- to eightfold more potent than T, whereas MNT was approximately equipotent to T. To assess the possible role of 5α-reduction in VP and SV growth, castrate immature rats were treated with maximally effective doses of T, DHT, DMA, MNT, or the related 19-norandrogen, 7α-methyl-19-nortestosterone (MENT), or vehicle, with or without dutasteride (DUT), an inhibitor of 5α-reductases types 1 and 2. In rats treated with T+DUT, serum T was significantly higher (P<0.05) than in rats treated with T alone, and serum DHT was decreased (P<0.001) to levels observed in castrate vehicle-treated rats. DUT significantly reduced both VP and SV weights in T-treated rats, whereas there was no significant effect of DUT on weights of these accessory sex glands in rats treated with DMA, MNT, DHT, or MENT. These results indicate that inhibition of 5α-reductase activity in vivo does not affect the androgenic potency of DMA, MNT, or MENT.

Copyright © 2010 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Effect of 5α-DHDMA compared to DMA and T after 7 days in the sc androgenic assay. 5α-DHDMA was less potent than DMA and more potent than T in increasing ventral prostate weight (A). DMA was more potent than 5α-DHDMA and T in increasing levator ani muscle weight (B). Groups with different letters are significantly different (P<0.05).
Fig. 2
Fig. 2
Effect of 5α-DHMNT compared to MNT and T after 7 days in the sc androgenic assay. 5α-DHMNT was more potent than MNT and T in increasing ventral prostate weight (A). MNT, 5α-DHMNT and T increased levator ani muscle weight compared to vehicle, but there was no significant difference among them at the highest doses (B). Groups with different letters are significantly different (P<0.05).
Fig. 3
Fig. 3
Effect of dutasteride on accessory sex gland weights after 8 days in the sc androgenic assay. Dutasteride significantly suppressed T-stimulated ventral prostate (*P<0.05) and seminal vesicle (**P<0.001) weights. There was no significant effect of dutasteride on accessory sex gland weights in rats treated with vehicle, DMA, or MNT.
Fig. 4
Fig. 4
Effect of dutasteride on serum androgen levels in the rats from Fig. 3. (A) In rats treated with T + dutasteride (DUT), there was a significant decrease in serum DHT levels (**P<0.001) and a significant increase in serum T levels (*P<0.05) compared to rats treated with T + vehicle (Veh). (B) There was a slight, but not significant (P=0.12), increase in serum DMA levels in rats treated with DMA + DUT compared to rats treated with DMA + Veh. In rats treated with MNT + DUT, serum levels of MNT were significantly elevated (*P<0.01) compared to rats treated with MNT + Veh.
Fig. 5
Fig. 5
Effect of dutasteride on accessory sex gland weights after 8 days in the sc androgenic assay. As in the experiment shown in Fig. 3, dutasteride significantly suppressed T-stimulated ventral prostate (*P<0.05) (A) and seminal vesicle (**P<0.001) (B) weights. There was no significant effect of dutasteride on accessory sex gland weights in rats treated with MENT or DHT. VP, but not SV, weights were increased in rats treated with vehicle + DUT (*P<0.05).
Fig. 6
Fig. 6
Effect of dutasteride on serum androgen levels in the rats from Fig. 5. (A) In rats treated with T + DUT, there was a significant decrease in serum DHT levels (**P<0.001) and a significant increase in serum T levels (*P<0.01) compared to rats treated with T + vehicle, confirming the results in Fig. 4A. (B) There was no significant difference in serum DHT levels (P=0.78) between rats treated with DHT + DUT or DHT + Veh. In rats treated with MENT + DUT, serum levels of MENT were significantly lower (**P<0.05) than in rats treated with MENT + Veh.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sundaram K, Kumar N, Monder C, Bardin CW. Different patterns of metabolism determine the relative anabolic activity of 19-norandrogens. J. Steroid Biochem. Mol. Biol. 1995;53:253–257. - PubMed
    1. Byrne MM, Nieschlag E. Testosterone replacement therapy in male hypogonadism. J Endocrinol. Invest. 2003;26:481–489. - PubMed
    1. Oettel M. The endocrine pharmacology of testosterone therapy in men. Naturwissenschaften. 2004;91:66–76. - PubMed
    1. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD, Mendelson CR, Bulun SE. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev. 1994;15:342–355. - PubMed
    1. Attardi BJ, Hild SA, Reel JR. Dimethandrolone undecanoate: a new potent orally active androgen with progestational activity. Endocrinology. 2006;14:3016–3026. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Elsevier Science full text link Elsevier Science Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp